Study Finds FDA Medical Device Adverse Event Summaries Frequently Lack Key Details
A BMJ study analyzed summary reports submitted to the FDA's MAUDE database from July 2019 to June 2025. It found many reports failed to identify device problems, undercounted events, or arrived late, potentially delaying safety signal detection. Researchers call for improvements to protect patients and meet FDA reporting standards.
The BMJ analysis examined every summary adverse-event report filed to MAUDE between July 2019 and June 2025. It covered 6,308 summaries containing 159,503 events, largely tied to high-risk devices. Many lacked a device or use problem, supplied insufficient information, were mislabeled as non-summary, or listed event counts incorrectly. More than half missed the FDA's 30-day deadline.
The FDA retired its Alternative Summary Reporting program in 2019 over concerns it hid safety signals, yet comparable exemptions persist. Summary submissions and their contained events more than doubled from 2020 to 2024. A linked editorial by Kyushu University Hospital's Koji Todaka raised transparency concerns and urged accurate, timely reporting, standardized device identifiers, and registry links.
Patients relying on implanted or high-risk devices could be affected if incomplete or late summaries delay recognition of dangerous malfunctions. Clinicians and regulators may gain less reliable postmarket evidence, potentially slowing recalls or safety communications. Manufacturers might face greater scrutiny and clearer reporting expectations. Improved accuracy, timeliness, and device identification may strengthen public confidence in FDA oversight, though the study's findings alone cannot show how many patients were harmed.